文献速递主动脉疾病

近肾主动脉瘤开窗式腔内主动脉修复术后的远期结局

Long-term outcomes after fenestrated endovascular aortic repair for juxtarenal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2021-11-25

本研究回顾性纳入2007至2011年在瑞典马尔默斯科讷大学医院血管中心连续接受开窗式腔内主动脉修复术(FEVAR)治疗近肾主动脉瘤的94例患者,中位随访89个月。结果显示技术成功率89.4%,5年主要靶血管通畅率89%±2%,37例(39.4%)需再干预,5年总生存率71.0%±4.7%;作者认为远期结果良好,FEVAR是近肾主动脉瘤的有效治疗选择。

要点

  • 94例近肾主动脉瘤患者接受FEVAR,中位随访89个月,技术成功率89.4%。
  • 5年主要靶血管通畅率89%±2%,37例(39.4%)共接受70次再干预。
  • 5年总生存率71.0%±4.7%,5例(5.3%)死于动脉瘤相关原因。

核心结论

  • 作者认为,FEVAR治疗近肾主动脉瘤的远期结果仍良好,治疗安全有效。
  • 尽管再干预需求仍高,远期肾功能和生存支持将FEVAR作为近肾主动脉瘤的有效治疗选择。

研究设计与样本

  • 回顾性研究,连续纳入2007至2011年在瑞典斯科讷大学医院血管中心接受FEVAR治疗的近肾主动脉瘤患者。
  • 共纳入94例患者,数据从病历和影像记录中回顾性收集。
  • 随访方案为术后1个月临床检查,术后1个月、12个月及此后每年行CT血管造影联合腹部平片。
  • 主要终点为靶血管不稳定、再干预和生存,同时分析动脉瘤直径变化、肾功能及内漏的发生率和类型。

主要发现

  • 共使用280个开窗或扇形凹口,其中205个置入支架。
  • 技术成功率为89.4%。
  • 主要靶血管通畅率1年为94%±1%,3年为90%±2%,5年为89%±2%。
  • 94例患者中37例(39.4%)共接受70次再干预,首次再干预的平均时间为21±3.97个月。
  • 5例(5.3%)死于动脉瘤相关原因;总生存率1年为95.7%±2.1%,3年为87.1%±3.5%,5年为71.0%±4.7%。

临床怎么用

  • 作者认为,FEVAR可作为近肾主动脉瘤的有效治疗选择,尽管再干预需求仍高。

局限性

  • 数据为回顾性收集。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Fenestrated endovascular aortic aneurysm repair (FEVAR) for juxtarenal aortic aneurysm (jAAA) disease is safe and effective with good short- and mid-term outcomes. The durability issues have mainly focused on the proximal and distal seal and target vessel (TV) instability, and long-term data are scarce. In previous studies, we have reported the short-term outcomes after FEVAR and compared our early and late experience and the long-term results for the early cohort. In the present report, we have provided the long-term outcomes for our late experience cohort who had undergone FEVAR at the Vascular Center (Skåne University Hospital, Malmö, Sweden). METHODS: Consecutive patients who had undergone FEVAR for jAAAs from 2007 to 2011 were included in the present study. Data were collected retrospectively from the medical and imaging records. The follow-up protocol consisted of a clinical examination 1 month postoperatively and computed tomography angiography combined with plain abdominal radiography at 1 and 12 months and annually thereafter. The primary endpoints were TV instability, reinterventions, and survival. Changes in the aneurysm diameter and renal function and the incidence and type of endoleaks were also analyzed. RESULTS: A total of 94 patients were included in the present study. The median follow-up time was 89 months (range, 0-152 months). A total of 280 fenestrations or scallops were used, of which 205 were stented. Technical success was 89.4%. Primary TV patency was 94% ± 1% at 1 year, 90% ± 2% at 3 years, and 89% ± 2% at 5 years. Of the 94 patients, 37 (39.4%) had required a total of 70 reinterventions. The mean time to the first reintervention was 21 ± 3.97 months. Five patients (5.3%) had died of aneurysm-related causes. Overall survival was 95.7% ± 2.1% at 1 year, 87.1% ± 3.5% at 3 years, and 71.0% ± 4.7% at 5 years. A stable or decreasing aortic diameter after treatment was seen in 91% of the cases. The mean glomerular filtration rate had decreased from 59.2 ± 14.9 mL/min/1.73 m2 preoperatively to 50.0 ± 18.6 mL/min/1.73 m2 at the end of follow-up. CONCLUSIONS: The results of the present study have shown that the long-term results after treatment of jAAAs with FEVAR remain good and the treatment is safe and effective. Although the need for reintervention remained high, long-term renal function and survival support the use of FEVAR as a valid treatment option for jAAA disease.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Sveinsson M, Sonesson B, Kristmundsson T, et al. Long-term outcomes after fenestrated endovascular aortic repair for juxtarenal aortic aneurysms. J Vasc Surg. 2021. PMID: 34838610. doi:10.1016/j.jvs.2021.11.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。